[Vectorcardiographic criteria with high diagnostic accuracy].
Explore the source record for details and available documents.
Adolescent↗
Biomedical subjects
I Sotobata
Publications and source records attributed to I Sotobata.
The changes in regional myocardial surface area during coronary occlusion and reperfusion.
For the analysis of regional myocardial function, the measurement of regional myocardial surface area (RMA) was performed on the epicardial surface of myocardial segment lengths in a direction parallel to the superficial myocardial fibers (SLa) and at right angles to the first (SLb). In eight anesthetized dogs with opened-chests, measurements were done during a 60 s left anterior descending coronary artery occlusion and reperfusion. In the ischemic region, coronary occlusion resulted in dyskinesis in RMA, and the reduction of it during the ejection phase (ERA) decreased significantly at 10 s (p less than 0.05) and thereafter (p less than 0.01). Regional myocardial work (EWA) from the pressure-area loops during the ejection phase also decreased significantly at 10 s (p less than 0.05) and thereafter (p less than 0.01). The end-diastolic RMA (EDRMA) increased significantly at 30 s (p less than 0.01) and thereafter (p less than 0.01). In the non-ischemic region, compensatory changes were shown, namely ERA, EWA and EDRMA, increased significantly during occlusion. After reperfusion, recovery to the control level was prompt, and only EDRMA remained the increased value after 30 s (p less than 0.01). Between SLa and SLb, characteristics differed from each other, which suggested that the directional differences of SLs should be considered when regional myocardial function is assessed from unidirectional SL. The changes in RMA reflect both changes of SLa and SLb during coronary occlusion and reperfusion, and were more marked than each SL. Thus, the usefulness of RMA to assess regional myocardial function was demonstrated during coronary occlusion and reperfusion.
Animals↗
Sex and age differences in ventricular gradient.
Sex and age differences of ventricular gradient (G) were analyzed and normal ranges were determined in normal Japanese subjects (120 men and 74 women), whose resting heart rate was within the range of 65 to 75 beats/min. Women showed a larger Z component in AT and a smaller Y and larger Z component in G than men. The common trend in age differences was a decrease in Y component of G in both men and women. The ranges obtained in the present study can be applied in automatic VCG analysis, in particular for the differentiation of primary and secondary ST-T changes.
Adult↗
Effects of oral elastase on lipid metabolism, platelet function, and blood coagulability in patients with diabetes mellitus.
Lipid metabolism, platelet function, and blood coagulability were evaluated in 20 patients with diabetes mellitus and stable fasting blood sugar levels before, during, and after treatment with the pancreatic enzyme elastase for 16 weeks. Serum high-density lipoprotein cholesterol levels increased from 46.9 mg/dl before treatment to 53.2 mg/dl after treatment (P less than 0.001) and serum triglyceride levels decreased from 151.4 to 125.4 mg/dl (P less than 0.05); no significant changes in total cholesterol levels were noted. Platelet counts in whole blood and in platelet-rich plasma increased from 17.1 and 27.5 X 10(4)/mm3, respectively, to 19.8 and 31.3 X 10(4)/mm3 after treatment (P less than 0.01 and less than 0.05). Plasma beta-thromboglobulin levels decreased from 117.0 to 72.7 ng/ml after treatment (P less than 0.001). No significant changes in platelet sensitivity to adenosine diphosphate aggregation were noted. Plasma fibrinogen and antithrombin III levels increased from 421.0 and 25.8 mg/dl, respectively, to 470.6 and 32.0 mg/dl after treatment (P less than 0.05 and less than 0.001). It is concluded that, since it has been shown that elastase improved lipid metabolism, inhibited platelet release, and increased antithrombin III levels, it may play a useful role in the prevention of vascular complications in diabetic patients.
Antithrombin III↗